Mesoangioblasts suppress T cell proliferation through IDO and PGE-2-dependent pathways

Stem Cells and Development

Volumn 22, Issue 3, 2013, Pages 512-523

  English, Karen ^a,d   Tonlorenzi, Rossana ^b   Cossu, Giulio ^b,c   Wood, Kathryn J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL CONTACT; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; MESOANGIOBLAST; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT STEM CELLS; ANTIGENS, CD; CELL COMMUNICATION; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; DINOPROSTONE; HLA ANTIGENS; HUMANS; IMMUNOMODULATION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872734102     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0386     Document Type: Article

References (42)

1. Dellavalle A, M Sampaolesi, R Tonlorenzi, E Tagliafico, B Sacchetti, L Perani, A Innocenzi, BG Galvez, G Messina, et al. (2007). Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol 9:255-267.
2. Tonlorenzi R, A Dellavalle, E Schnapp, G Cossu and M Sampaolesi. (2007). Isolation and characterization of mesoangioblasts from mouse, dog, and human tissues. Curr Protoc Stem Cell Biol Chapter 2:Unit 2B 1.
3. Sampaolesi M, Y Torrente, A Innocenzi, R Tonlorenzi, G D'Antona, MA Pellegrino, R Barresi, N Bresolin, MG De Angelis, et al. (2003). Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 301:487-492.
4. Sampaolesi M, S Blot, G D'Antona, N Granger, R Tonlorenzi, A Innocenzi, P Mognol, JL Thibaud, BG Galvez, et al. (2006). Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444:574-579.
5. Tedesco FS, A Dellavalle, J Diaz-Manera, G Messina and G Cossu. (2010). Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest 120:11-19.
6. Tajbakhsh S. (2009). Skeletal muscle stem cells in developmental versus regenerative myogenesis. J Intern Med 266:372-389.
7. Boyd AS and KJ Wood. (2010). Characteristics of the early immune response following transplantation of mouse ES cell derived insulin-producing cell clusters. PLoS One 5:e10965.
8. Swijnenburg RJ, M Tanaka, H Vogel, J Baker, T Kofidis, F Gunawan, DR Lebl, AD Caffarelli, JL de Bruin, EV Fedoseyeva and RC Robbins. (2005). Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 112:I166-I172.
9. Zhao T, ZN Zhang, Z Rong, and Y Xu. (2011). Immunogenicity of induced pluripotent stem cells. Nature 474:212-215.
10. Evans NP, SA Misyak, JL Robertson, J Bassaganya-Riera and RW Grange. (2009). Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention. PM R 1:755-768.
11. Chen YW, P Zhao, R Borup and EP Hoffman. (2000). Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 151:1321-1336.
12. Evans NP, SA Misyak, JL Robertson, J Bassaganya-Riera and RW Grange. (2009). Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy. Am J Phys Med Rehabil 88:502-522.
13. Marotta M, C Ruiz-Roig, Y Sarria, JL Peiro, F Nunez, J Ceron, F Munell and M Roig-Quilis. (2009). Muscle genomewide expression profiling during disease evolution in mdx mice. Physiol Genomics 37:119-132.
14. Porter JD, S Khanna, HJ Kaminski, JS Rao, AP Merriam, CR Richmonds, P Leahy, J Li, W Guo and FH Andrade. (2002). A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 11:263-272.
15. Porreca E, MD Guglielmi, A Uncini, P Di Gregorio, A Angelini, C Di Febbo, SD Pierdomenico, G Baccante and F Cuccurullo. (1999). Haemostatic abnormalities, cardiac involvement and serum tumor necrosis factor levels in Xlinked dystrophic patients. Thromb Haemost 81:543-546.
16. Pierno S, B Nico, R Burdi, A Liantonio, MP Didonna, V Cippone, B Fraysse, JF Rolland, D Mangieri, et al. (2007). Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. Neuropathol Appl Neurobiol 33:344-359.
17. BartholomewA,CSturgeon,MSiatskas,KFerrer,KMcIntosh, S Patil, W Hardy, S Devine, D Ucker, et al. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30:42-48.
18. English K and KJ Wood. (2010). Immunogenicity of embryonic stem cell-derived progenitors after transplantation. Curr Opin Organ Transplant [Epub ahead of print].
19. Hori J, TF Ng, M Shatos, H Klassen, JW Streilein and MJ Young. (2003). Neural progenitor cells lack immunogenicity and resist destruction as allografts. Stem Cells 21:405-416.
20. Ding Y, D Xu, G Feng, A Bushell, RJ Muschel and KJ Wood. (2009). Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and-9. Diabetes 58:1797-1806.
21. English K, FP Barry and BP Mahon. (2008). Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 115:50-58.
22. English K, A French and KJ Wood. (2010). Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 7:431-442.
23. Highfill SL, RM Kelly, MJ O'Shaughnessy, Q Zhou, L Xia, A Panoskaltsis-Mortari, PA Taylor, J Tolar and BR Blazar. (2009). Multipotent adult progenitor cells can suppress graftversus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming. Blood 114:693-701.
24. Wang L, J Shi, FW van Ginkel, L Lan, G Niemeyer, DR Martin, EY Snyder and NR Cox. (2009). Neural stem/progenitor cells modulate immune responses by suppressing T lymphocytes with nitric oxide and prostaglandin E2. Exp Neurol 216:177-183.
25. Yachimovich-Cohen N, S Even-Ram, Y Shufaro, J Rachmilewitz and B Reubinoff. (2010). Human embryonic stem cells suppress T cell responses via arginase I-dependent mechanism. J Immunol 184:1300-1308.
26. Dellavalle A, G Maroli, D Covarello, E Azzoni, A Innocenzi, L Perani, S Antonini, R Sambasivan, S Brunelli, S Tajbakhsh and G Cossu. (2011). Pericytes resident in postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells. Nat Commun 2:499.
27. Roobrouck VD, C Clavel, SA Jacobs, F Ulloa-Montoya, S Crippa, A Sohni, SJ Roberts, FP Luyten, SW Van Gool, et al. (2011). Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells 29:871-882.
28. Crisan M, S Yap, L Casteilla, CW Chen, M Corselli, TS Park, G Andriolo, B Sun, B Zheng et al. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3:301-313.
29. Carvalho-Gaspar M, JS Billing, BM Spriewald and KJ Wood. (2005). Chemokine gene expression during allograft rejection: comparison of two quantitative PCR techniques. J Immunol Methods 301:41-52.
30. Harris SG, J Padilla, L Koumas, D Ray and RP Phipps. (2002). Prostaglandins as modulators of immunity. Trends Immunol 23:144-150.
31. Mellor AL and DH Munn. (2000). Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annu Rev Immunol 18:367-391.
32. English K, FP Barry, CP Field-Corbett and BP Mahon. (2007). IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 110:91-100.
33. Prasanna SJ, D Gopalakrishnan, SR Shankar and AB Vasandan. (2010). Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 5:e9016.
34. Ren G, L Zhang, X Zhao, G Xu, Y Zhang, AI Roberts, RC Zhao and Y Shi. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2:141-150.
35. Polchert D, J Sobinsky, G Douglas, M Kidd, A Moadsiri, E Reina, K Genrich, S Mehrotra, S Setty, Smith B and Bartholomew A. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38:1745-1755.
36. Hoffman RA, RS Mahidhara, AS Wolf-Johnston, L Lu, AW Thomson and RL Simmons. (2002). Differential modulation of CD4 and CD8 T-cell proliferation by induction of nitric oxide synthesis in antigen presenting cells. Transplantation 74:836-845.
37. Parks WC, CL Wilson and YS Lopez-Boado. (2004). Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:617-629.
38. Guttinger M, E Tafi, M Battaglia, M Coletta and G Cossu. (2006). Allogeneic mesoangioblasts give rise to alpha-sarcoglycan expressing fibers when transplanted into dystrophic mice. Exp Cell Res 312:3872-3879.
39. Lolmede K, L Campana, M Vezzoli, L Bosurgi, R Tonlorenzi, E Clementi, ME Bianchi, G Cossu, AA Manfredi, S Brunelli and P Rovere-Querini. (2009). Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1-and MMP-9-dependent pathways. J Leukoc Biol 85: 779-787.
40. Palumbo R, BG Galvez, T Pusterla, F De Marchis, G Cossu, KB Marcu and ME Bianchi. (2007). Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 179:33-40.
41. Galvez BG, M Sampaolesi, S Brunelli, D Covarello, M Gavina, B Rossi, G Constantin, Y Torrente and G Cossu. (2006). Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability. J Cell Biol 174:231-243.
42. Sachs DH. (2003). Tolerance: of mice and men. J Clin Invest 111:1819-1821.